Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study

Edward Burn, Seng Chan You, Anthony G. Sena, Kristin Kostka, Hamed Abedtash, Maria Tereza F. Abrahão, Amanda Alberga, Heba Alghoul, Osaid Alser, Thamir M. Alshammari, Maria Aragon, Carlos Areia, Juan M. Banda, Jaehyeong Cho, Aedin C. Culhane, Alexander Davydov, Frank J. DeFalco, Talita Duarte-Salles, Scott DuVall, Thomas Falconer, Sergio Fernandez-Bertolin, Weihua Gao, Asieh Golozar, Jill Hardin, George Hripcsak, Vojtech Huser, Hokyun Jeon, Yonghua Jing, Chi Young Jung, Benjamin Skov Kaas-Hansen, Denys Kaduk, Seamus Kent, Yeesuk Kim, Spyros Kolovos, Jennifer C. E. Lane, Hyejin Lee, Kristine E. Lynch, Rupa Makadia, Michael E. Matheny, Paras P. Mehta, Daniel R. Morales, Karthik Natarajan, Fredrik Nyberg, Anna Ostropolets, Rae Woong Park, Jimyung Park, Jose D. Posada, Albert Prats-Uribe, Gowtham Rao, Christian Reich, Yeunsook Rho, Peter Rijnbeek, Lisa M. Schilling, Martijn Schuemie, Nigam H. Shah, Azza Shoaibi, Seokyoung Song, Matthew Spotnitz, Marc A. Suchard, Joel N. Swerdel, David Vizcaya, Salvatore Volpe, Haini Wen, Andrew E. Williams, Belay B. Yimer, Lin Zhang, Oleg Zhuk, Daniel Prieto-Alhambra () and Patrick Ryan
Additional contact information
Edward Burn: Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
Seng Chan You: Ajou University School of Medicine
Anthony G. Sena: Janssen Research and Development
Kristin Kostka: Real World Solutions, IQVIA
Hamed Abedtash: Eli Lilly and Company
Maria Tereza F. Abrahão: Faculty of Medicine, University of Sao Paulo
Amanda Alberga: Observational Health Data Sciences and Informatics Network
Heba Alghoul: Faculty of Medicine, Islamic University of Gaza
Osaid Alser: Massachusetts General Hospital, Harvard Medical School
Thamir M. Alshammari: Medication Safety Research Chair, King Saud University
Maria Aragon: Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
Carlos Areia: University of Oxford
Juan M. Banda: Georgia State University
Jaehyeong Cho: Ajou University School of Medicine
Aedin C. Culhane: Data Science, Dana-Farber Cancer Institute. Biostatistics, Harvard TH Chan School of Public Health
Alexander Davydov: Odysseus Data Services, Inc.
Frank J. DeFalco: Janssen Research and Development
Talita Duarte-Salles: Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
Scott DuVall: Department of Veterans Affairs
Thomas Falconer: Columbia University
Sergio Fernandez-Bertolin: Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
Weihua Gao: Health Economics and Outcomes Research, AbbVie
Asieh Golozar: Pharmacoepidemiology
Jill Hardin: Janssen Research and Development
George Hripcsak: Columbia University
Vojtech Huser: National Library of Medicine, National Institutes of Health
Hokyun Jeon: Ajou University Graduate School of Medicine
Yonghua Jing: Health Economics and Outcomes Research, AbbVie
Chi Young Jung: Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University Medical Center
Benjamin Skov Kaas-Hansen: Clinical Pharmacology Unit, Zealand University Hospital
Denys Kaduk: Odysseus Data Services, Inc.
Seamus Kent: Science Policy and Research, National Institute for Health and Care Excellence
Yeesuk Kim: Hanyang University
Spyros Kolovos: University of Oxford
Jennifer C. E. Lane: University of Oxford
Hyejin Lee: Health Insurance Review & Assessment Service
Kristine E. Lynch: Department of Veterans Affairs
Rupa Makadia: Janssen Research and Development
Michael E. Matheny: GRECC, Tennessee Valley Healthcare System VA
Paras P. Mehta: University of Arizona
Daniel R. Morales: University of Dundee
Karthik Natarajan: Columbia University
Fredrik Nyberg: University of Gothenburg
Anna Ostropolets: Columbia University
Rae Woong Park: Ajou University School of Medicine
Jimyung Park: Ajou University Graduate School of Medicine
Jose D. Posada: Stanford University
Albert Prats-Uribe: Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford
Gowtham Rao: Janssen Research and Development
Christian Reich: Real World Solutions, IQVIA
Yeunsook Rho: University of Oxford
Peter Rijnbeek: Erasmus University Medical Center
Lisa M. Schilling: University of Colorado Anschutz Medical Campus
Martijn Schuemie: Janssen Research and Development
Nigam H. Shah: Stanford University
Azza Shoaibi: Janssen Research and Development
Seokyoung Song: Catholic University of Daegu, School of Medicine
Matthew Spotnitz: Columbia University
Marc A. Suchard: University of California
Joel N. Swerdel: Janssen Research and Development
David Vizcaya: Bayer Pharmaceuticals
Salvatore Volpe: Columbia University
Haini Wen: Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Andrew E. Williams: Tufts Institute for Clinical Research and Health Policy Studies
Belay B. Yimer: Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester
Lin Zhang: School of Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences
Oleg Zhuk: Odysseus Data Services, Inc.
Daniel Prieto-Alhambra: Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford
Patrick Ryan: Janssen Research and Development

Nature Communications, 2020, vol. 11, issue 1, 1-11

Abstract: Abstract Comorbid conditions appear to be common among individuals hospitalised with coronavirus disease 2019 (COVID-19) but estimates of prevalence vary and little is known about the prior medication use of patients. Here, we describe the characteristics of adults hospitalised with COVID-19 and compare them with influenza patients. We include 34,128 (US: 8362, South Korea: 7341, Spain: 18,425) COVID-19 patients, summarising between 4811 and 11,643 unique aggregate characteristics. COVID-19 patients have been majority male in the US and Spain, but predominantly female in South Korea. Age profiles vary across data sources. Compared to 84,585 individuals hospitalised with influenza in 2014-19, COVID-19 patients have more typically been male, younger, and with fewer comorbidities and lower medication use. While protecting groups vulnerable to influenza is likely a useful starting point in the response to COVID-19, strategies will likely need to be broadened to reflect the particular characteristics of individuals being hospitalised with COVID-19.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18849-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18849-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18849-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().